Orgenesis Stock Beta
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis OTC Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis otc stock.
Orgenesis |
Orgenesis OTC Stock Beta Analysis
Orgenesis' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Orgenesis Beta | 1.21 |
Most of Orgenesis' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Orgenesis has a Beta of 1.206. This is 40.23% higher than that of the Biotechnology sector and 13.24% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Orgenesis Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Orgenesis will likely underperform.
Orgenesis Fundamentals
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Shares Owned By Insiders | 21.16 % | ||||
| Shares Owned By Institutions | 4.54 % | ||||
| Number Of Shares Shorted | 56.25 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 530 K | ||||
| Gross Profit | 36.02 M | ||||
| EBITDA | (54.07 M) | ||||
| Net Income | (64.92 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.57 X | ||||
| Book Value Per Share | (3.30) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (8.00) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 146 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 10.07 M | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | (12.33 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |